ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1709

Utilization of Complementary and Integrative Medicine Among Lupus Patients:a Patient Centered Analysis of Perceived Effectiveness and Preference

Lindsey Warner and Shazia Beg, University of Central Florida College of Medicine, Orlando, FL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: alternative medicine, complementary alternative medicine and patient preferences, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Lupus is an autoimmune disease with multitude of symptoms that are often not fully controlled by standard biomedical treatments. This study was designed to gauge current patient use and perspective on Complementary and Integrative Medicine (CIM) therapies. To our knowledge the last poll of CIM use in this patient population was that of the tri-nation study in 1997.

Methods:

85 participants were recruited from an academic rheumatology practice, lupus support groups, lupus foundation listservs and lupus walks. Of the 85 participants, 77 completed the Qualtrics survey and were used in the data analysis.

The survey was organized into five sections correlating with 5 major branches of CIM therapies: manipulative and body based, mind body, biologically based, alternative medical systems and energy healing.The participant was then asked to answer five questions regarding each of the 20 modalities included. These questions ask the following: (1) whether they have used the therapy, (2) how often, (3) what motivates them to utilize the therapy, (4) what symptoms are they trying to address, and (5) how effective do they perceive the therapy to be.

Results:

The three most commonly used modalities among patients with lupus were non-herbal natural products 44 (57%), aromatherapy/ essential oils 32 (41.5%) and meditation 31 (40.2%). Non-herbal natural products include chondroitin, coenzyme Q 10, fish oil, omega 3 and DHA, glucosamine, lutein, melatonin, Methylsulfonylmethane (MSM), and sesame oil. The most commonly utilized were natural fats 40 (90.9%) (fish oil, omega 3, and DHA). This was followed by melatonin 13 (29.5), and glucosamine 11 (25 %). Despite their high rate of utilization, over a third of participants [17 (38.6%)] felt that they were not effective or only somewhat effective. 21 (67.7%) of the meditation users found their therapy to be effective, very effective, or extremely effective. The majority of respondents in all three groups indicated that their motivation for utilizing these therapies was because “they believed it worked” and when asked about their desired benefit indicated “general wellness.” This was a common theme for and was reported as the motivation and benefit for 10 of the 19 therapies. The most striking deviation from this theme however was herbal medicine, with (22; 84.6%) reporting motivation was relief of a lupus related symptom. 91.7% of the 26 respondents that utilized herbs did so specifically to alleviate lupus-related symptoms rather than general wellness, with 20 (76.9%) reporting benefit. Of the 20 herbs listed, turmeric (7; 26.9%), marijuana (6; 23.1%), and green tea (2; 7.6%) were reported to be most beneficial for lupus-related symptoms.

Conclusion: The rate of CIM utilization reported by our lupus patient sample was 87.6%, which is approximately three times higher than the 2012 National Health Statistic Reports estimated 33.2% for the general U.S. population. Like the general public, our respondents gravitated towards the supplement industry. Modalities that had highest perceived effectiveness included massage, herbal medicines, and meditation and may provide therapeutic benefit. Future research should be done to explore efficacy of these therapies in larger lupus population.


Disclosure: L. Warner, None; S. Beg, None.

To cite this abstract in AMA style:

Warner L, Beg S. Utilization of Complementary and Integrative Medicine Among Lupus Patients:a Patient Centered Analysis of Perceived Effectiveness and Preference [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/utilization-of-complementary-and-integrative-medicine-among-lupus-patientsa-patient-centered-analysis-of-perceived-effectiveness-and-preference/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utilization-of-complementary-and-integrative-medicine-among-lupus-patientsa-patient-centered-analysis-of-perceived-effectiveness-and-preference/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology